Androgen‐independent Effects of Serenoa repens Extract (Prostasan®) on Prostatic Epithelial Cell Proliferation and Inflammation
- 8 June 2011
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 26 (2) , 259-264
Abstract
Extracts from Serenoa repens are widely used for the treatment of benign prostatic hyperplasia (BPH) and traditionally for prostatitis. In the present study we evaluated the biological effects of Serenoa repens extract (Prostasan®) on prostate cells beyond its known antiandrogenic actions. Prostasan® inhibited epidermal growth factor (EGF) and lipopolysaccharide (LPS) induced proliferation of the prostatic epithelial, androgen independent cell line PC‐3. At effective concentrations of 50 µg/mL, Prostasan® partly displaced EGF from EGF receptor (EGFR) but fully blocked EGF‐induced cell proliferation of PC‐3 cells. Similarly, Prostasan® inhibited LPS‐induced proliferation of PC‐3 cells without affecting LPS activation of the NFĸB pathway via toll‐like receptor‐4 (TLR‐4). Additionally, Prostasan® reduced the constitutive secretion of monocyte chemotactic protein‐1 (MCP‐1), the LPS‐induced secretion of IL‐12 and inhibited MCP‐1 and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) production in the presence of LPS on PC‐3 cells. Taken together, our results suggest that S. repens extracts, in addition to other reported effects on BPH development and prostatitis, inhibits EGF‐dependent growth and proinflammatory responses of the prostate epithelial cells. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Monocyte chemotactic protein‐1 (MCP‐1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasiaThe Prostate, 2009
- Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisThe Prostate, 2009
- Serenoa repensfor benign prostatic hyperplasia2009
- Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasiaNutrition Research and Practice, 2009
- Lipido‐sterolic extract of Serenoa repens (LSESr, Permixon®) treatment affects human prostate cancer cell membrane organizationJournal of Cellular Physiology, 2008
- Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptomsCurrent Prostate Reports, 2008
- Effects of Homeopathic Preparations on Human Prostate Cancer Growth in Cellular and Animal ModelsIntegrative Cancer Therapies, 2006
- Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activityThrombosis and Haemostasis, 2005
- Serenoa repens (Permixon®) inhibits the 5α‐reductase activity of human prostate cancer cell lines without interfering with PSA expressionInternational Journal of Cancer, 2004
- Effect of permixon on human prostate cell growth: Lack of apoptotic actionThe Prostate, 2004